Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.


Tatar B., Köse Ş., Ergun N., Turken M., Onlen Y., Yılmaz Y., ...More

Revista da Associacao Medica Brasileira (1992), vol.65, pp.1470-1475, 2019 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 65
  • Publication Date: 2019
  • Doi Number: 10.1590/1806-9282.65.12.1470
  • Journal Name: Revista da Associacao Medica Brasileira (1992)
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.1470-1475
  • Keywords: Hepatitis C, End-Stage Renal Disease, Sustained Virologic Response, SUSTAINED VIRAL RESPONSE, VIRUS GENOTYPES, INFECTION, INTERFERON, METAANALYSIS, EFFICACY, OMBITASVIR/PARITAPREVIR/RITONAVIR, COMBINATION, IMPAIRMENT, MANAGEMENT

Abstract

OBJECTIVE:

The recent development of direct-acting antiviral agents (DAAs) has dramatically changed the treatment of chronic hepatitis C, and interferon-based regimes have become a poor treatment choice in clinical practice. Today DAAs offer shorter, well-tolerated, highly effective curative therapies. This study aimed to evaluate the effectiveness and safety of DAAs in patients with end-stage renal disease and HCV genotype 1 infection in real clinical practice.

METHODS:

Thirty-six patients who attended our clinic, were diagnosed with chronic hepatitis C (CHC), undergoing hemodialysis, and fulfilled the criteria of age >18 years, genotype 1 infection, with a detectable HCV RNA level were considered for the study. Patients with GT1a infection received OBV/PTV/r plus DSV plus RBV for 12 weeks; GT1b infected patients received this regimen without RBV for 12 weeks.

RESULTS:

The study was conducted on 33 patients. The mean age was 52.30 ±13.77 years, and 70 % of them were male. By the fourth week of treatment, HCV RNA levels decreased below 15 IU/ml in all patients. Sustained virologic response (SVR) 12 rate was 100%. Nine patients had side effects during treatment. Of the patients with side effects, 89.9% were in group 1a and 11.1% in group 1b.

CONCLUSION:

In this study, treatment with OBV/PTV/r and DSV with or without RBV resulted in high rates of sustained virologic response in HCV GT1-infected patients with end-stage renal disease (ESRD). SVR was achieved in all patients with few side effects.